Which longevity startups are closest to a real commercial drug?
In our longevity market deck, you will find everything you need to understand the market
SUMMARY
Insilico Medicine is the longevity startup closest to a real commercial human drug, because rentosertib has already reached Phase III while the strongest competing longevity programs remain in Phase I or II.
That does not mean the first commercial longevity drug will be approved for “aging.” The practical route is still to turn discoveries from aging biology into treatments for recognizable diseases such as pulmonary fibrosis, cardiovascular disease, Alzheimer's disease or retinal disorders.
Insilico has a meaningful lead because rentosertib has moved beyond biomarkers and small safety studies. Its Phase IIa trial produced peer-reviewed human efficacy data, and its Phase III study expands the test to 320 patients over 52 weeks with lung function as the primary endpoint.
The strongest chasing group is less clear-cut. BioAge has unusually strong human pharmacology for BGE-102, Longeveron already has randomized Phase II evidence and FDA engagement around a Phase III Alzheimer's program, and Cambrian has moved ATX-304 from metabolic signals toward mid-stage development.
Commercial proximity and scientific ambition are almost inverted in parts of the sector. Life Biosciences, Retro Biosciences and NewLimit are attempting interventions that look more like genuine rejuvenation, but their programs remain much earlier than a conventional disease drug such as rentosertib.
Rubedo sits in an interesting middle ground. Its drug directly targets pathological senescent cells, but it is using dermatology as a faster proving ground where lesions can be seen, biopsied and measured within weeks instead of waiting years for lifespan or cardiovascular outcomes.
The history of Unity Biotechnology is a useful warning against ranking companies by the highest trial phase they have ever reached. UBX1325 made it to Phase IIb, but a missed primary analysis and financial pressure ultimately pushed Unity out of active clinical development.
Longeveron is also closer than its reputation suggests. Laromestrocel has already generated randomized Phase IIb data in aging-related frailty, while its Alzheimer's program has received RMAT designation and moved far enough through FDA discussions to have an aligned Phase III design.
Loyal may beat every human longevity company to the literal milestone of legally selling a lifespan-extension drug. Its LOY-002 program for senior dogs has already cleared two major FDA technical sections required for expanded conditional approval, leaving manufacturing work as the major remaining regulatory piece.
The sector is therefore splitting into two races. Insilico leads the race to commercialize a human medicine born from aging biology, while companies such as Life Biosciences and Retro are beginning the much harder test of whether interventions aimed more directly at rejuvenation can work safely in people.
Nobody has yet produced a large controlled human trial showing that a medicine broadly slows aging across the body. Insilico is closest to the first commercial step, but the much bigger claim — a drug that regulators can accept as actually slowing human aging — is still wide open.
This market map, featured in our longevity market deck, highlights top companies and startups in the longevity market
What does “closest to a real commercial drug” mean for a longevity startup?
The longevity startup closest to a real commercial drug is the one nearest approval for a human treatment that came out of aging biology, even if the eventual label says “pulmonary fibrosis” or “cardiovascular disease” rather than “longevity.”
That definition separates three races that are often mixed together. One is the race to sell any human medicine discovered through geroscience. Another is the race to prove that directly targeting a hallmark of aging can treat disease. The hardest one is producing a medicine that regulators accept because it broadly slows aging or extends healthy lifespan.
Those races currently have different leaders. Insilico Medicine has rentosertib in Phase III for idiopathic pulmonary fibrosis. BioAge and Cambrian have aging-linked small molecules around Phase II. Longeveron has already produced Phase II data in aging-related frailty and has aligned with the FDA on a Phase III Alzheimer's study design. Rubedo is testing a senescence-targeting drug in humans. Life Biosciences and Retro Biosciences have crossed into Phase I with more radical rejuvenation or aging-directed programs. Loyal is even closer to selling a drug explicitly designed to extend healthy lifespan, except that its patients are dogs.
| What are we measuring? | Closest company or program now |
|---|---|
| Human medicine built from aging biology | Insilico Medicine, rentosertib |
| Human geroscience drug with Phase II development | BioAge, Cambrian and Longeveron |
| Direct cellular rejuvenation in humans | Life Biosciences, ER-100 |
| Aging-focused small molecule already in Phase I | Retro Biosciences, RTR242 |
| Explicit lifespan-extension drug near legal sale | Loyal, LOY-002 for dogs |
| Human drug approved to slow aging itself | Nobody |
Why can’t a longevity startup simply run a trial for “aging”?
Human longevity startups still cannot follow a normal FDA path for a drug whose indication is simply “aging,” so almost every serious company is entering the market through a conventional disease first.
The problem starts with the endpoint. A regulator can measure whether an IPF drug slows loss of lung capacity or whether an Alzheimer's treatment slows cognitive decline. “People age more slowly” is much harder to turn into a practical registration trial. A definitive lifespan study could take years or decades, while biological-age clocks have not become validated substitutes for clinical benefit.
Safety makes the problem even harder. A medicine for healthy 65-year-olds might eventually be taken for years by millions of people. Regulators can tolerate substantial toxicity from a cancer treatment when the alternative is death within months. The acceptable risk for preventive longevity medicine would be dramatically lower.
The National Institute on Aging has specifically highlighted indication choice, patient selection, dosing, endpoints and risk-benefit assessment as unresolved issues when geroscience programs enter FDA review.
That explains why the clinical pipelines look surprisingly conventional. Insilico chose pulmonary fibrosis. BioAge is pursuing cardiovascular and retinal disease. Cambrian is working through obesity and metabolic disease. Life Biosciences chose optic neuropathies. Retro's first clinical asset is being developed around Alzheimer's disease.
As this slide shows, and as featured in our longevity market deck, online search interest in longevity has been steadily increasing
Is Insilico Medicine the longevity startup closest to a human drug today?
Yes. Insilico Medicine is currently the clearest human-market leader because rentosertib has entered Phase III, while almost every other serious longevity startup remains in Phase I or II.
Rentosertib is an oral inhibitor of TNIK being developed for idiopathic pulmonary fibrosis, a progressive fibrotic lung disease strongly associated with age. Insilico identified TNIK using its AI drug-discovery platform, which was built partly around aging biology, and then designed the molecule computationally.
Its Phase IIa trial gives us actual human efficacy evidence rather than another animal result. The study enrolled 71 people with IPF and tested three rentosertib doses against placebo for 12 weeks. At 60 mg daily, mean forced vital capacity increased by 98.4 mL, while the placebo group declined by 20.3 mL. Nature Medicine published the full study rather than leaving us with company-presented topline numbers.
Insilico has now moved into a 320-patient Phase III trial running for 52 weeks. The primary endpoint is annualized change in forced vital capacity. That's a completely different level of clinical commitment from a 20-person Phase I safety trial.
A fresh development strengthens the aging connection without changing the ranking. A newly published Nature Biotechnology analysis used six separate proteomic aging clocks on blood samples from the Phase IIa study. All six estimated lower biological age after treatment. Interesting, yes. Proof that rentosertib slows human aging, no. Aging clocks remain exploratory biomarkers here, while the Phase III trial will live or die on clinically meaningful lung outcomes.
If you want more recent data on this point, please see our latest longevity market report.
Does rentosertib really count as a longevity drug — and could Phase III still derail it?
Rentosertib counts as a drug created from longevity science, but its Phase III trial still has to prove that the early IPF result is real, durable and commercially useful.
The commercial product Insilico is trying to approve treats idiopathic pulmonary fibrosis. A successful label would say something about IPF, dosing and patient eligibility. It would not say that rentosertib extends lifespan or makes people biologically younger.
Still, the geroscience connection is stronger than simple marketing. Insilico's discovery system incorporated aging biology, TNIK emerged from that work, and fibrosis is deeply intertwined with aging. IPF incidence rises sharply in older adults, while progressive tissue fibrosis is one of the processes geroscience researchers have spent years trying to understand.
The new proteomic-aging analysis adds another layer. Six independently developed clocks moved in the same direction in rentosertib-treated patients, and the changes tracked with the dose-dependent lung-function findings. That repeated result across six models makes the observation harder to dismiss as one quirky algorithm.
We should keep the conclusion narrow, though. These clocks estimate biological age from patterns in circulating proteins. They have not shown that the patients will live longer, avoid multiple age-related diseases or remain healthier for more years.
The bigger near-term question is Phase III. The attractive Phase II number — a 98.4 mL mean FVC improvement at the highest dose — came from just 18 patients followed for 12 weeks. FVC was also a secondary efficacy endpoint. The placebo arm contained 17 patients, and one participant had an unusually large difference between screening and baseline lung measurements.
The Phase III study raises the standard in exactly the places where Phase II was weakest. Enrollment goes from 71 people across all arms to 320. Treatment expands from 12 weeks to 52. FVC decline becomes the primary endpoint.
Commercial competition has also become tougher. Boehringer Ingelheim's nerandomilast has since won FDA approval as Jascayd for IPF after large 52-week trials showed slower FVC decline than placebo. Rentosertib would therefore enter a market that already has pirfenidone, nintedanib and a newly approved oral competitor.
If rentosertib survives that test, Insilico will have something much more important than an interesting aging-clock result: a late-stage drug born from aging biology with conventional clinical evidence behind it.
| Rentosertib | Where it stands |
|---|---|
| Phase IIa enrollment | 71 patients |
| Highest-dose mean FVC change | +98.4 mL over 12 weeks |
| Current development stage | Phase III |
| Phase III enrollment | 320 patients |
| Phase III duration | 52 weeks |
| Main Phase III endpoint | Annualized FVC change |
| Approved today | No |
This chart, featured in our longevity market deck, illustrates yearly VC funding for longevity startups
Is BioAge the strongest pure longevity drug company behind Insilico?
BioAge is one of the strongest pure geroscience contenders because BGE-102 has moved quickly into Phase II and its early human pharmacology is unusually strong, although BioAge still has a major efficacy gap to close.
BGE-102 inhibits NLRP3, a central inflammatory pathway linked to chronic age-related inflammation. BioAge found the program through its broader effort to connect human aging biology with drug targets, so the longevity link is direct.
The Phase I numbers were striking. Among people with obesity and elevated inflammation, 60 mg of BGE-102 reduced median high-sensitivity C-reactive protein by 85% after seven days and 86% after 21 days. Thirteen of 15 participants in that cohort reached hsCRP below 2 mg/L by day 21. At 120 mg, BioAge reported another 86% median reduction after 14 days. The company also saw strong suppression of IL-1β in an ex-vivo assay and reported no serious adverse events or treatment-related discontinuations across the tested dose levels.
BioAge has since started QUELL-CV, a randomized Phase II trial in roughly 160 adults with obesity, elevated inflammation and at least one additional cardiovascular risk factor. Three BGE-102 doses are being compared with placebo for 12 weeks.
Here's the catch: the primary endpoint is still hsCRP. Lowering an inflammatory biomarker is useful evidence that the drug hits NLRP3 in humans, but patients ultimately care about heart attacks, strokes, disability and survival. BioAge describes QUELL-CV largely as a dose-ranging proof-of-concept study intended to support later development.
The company also plans to test BGE-102 in diabetic macular edema, giving the same molecule another route into a defined age-related disease.
BioAge's previous lead azelaprag is also worth remembering. The APJ agonist had already entered Phase II obesity testing when liver enzyme elevations forced the program to stop. BGE-102 is effectively the company's second serious attempt to turn its longevity platform into a commercial drug.
If you want more recent data on this point, please see our latest longevity market report.
How close is Cambrian Bio’s ATX-304 to becoming a real drug?
Cambrian's ATX-304 has reached the point where we can take it seriously as a commercial drug candidate, but Phase II still has to show that its interesting metabolic effects translate into enough benefit for patients.
ATX-304 activates AMPK, one of the body's main cellular energy sensors. AMPK activity is heavily studied in aging and metabolic biology, which gives the program a genuine geroscience foundation. Cambrian is taking the easier commercial route through obesity and cardiometabolic disease.
In its Phase Ib study involving adults with obesity and prediabetes, Cambrian reported improvements across liver fat, visceral fat, triglycerides, adiponectin and resting metabolic rate. The company has since moved the program toward Phase II and has explored combining ATX-304 with semaglutide.
That combination idea is commercially interesting. GLP-1 drugs are excellent at suppressing appetite and reducing weight, but a complementary drug that changes energy expenditure or body composition could occupy a different part of the obesity market.
We still do not know whether ATX-304 can produce a clinically compelling amount of weight loss or metabolic improvement in a randomized Phase II population. Changes in liver fat and resting metabolic rate can point in the right direction without necessarily becoming a competitive pharmaceutical product.
Cambrian also has a broader longevity pipeline, including selective mTORC1 work backed by up to $30.8 million from ARPA-H. For commercial proximity, though, ATX-304 is the program that matters today.
This chart, featured in our longevity market deck, looks at Function Health’s strategy in longevity
Could Rubedo get a senolytic drug to market before the bigger longevity companies?
Rubedo could become one of the first longevity startups to commercialize a drug that directly targets pathological senescent cells, although its current human evidence is still early and comes from small dermatology studies.
RLS-1496 modulates GPX4 and is designed to selectively eliminate or alter pathological senescent cells involved in chronic inflammation and tissue damage. That puts Rubedo much closer to classical longevity biology than a company simply developing a normal drug for an older patient population.
Rubedo began human testing in 2025. The company first reported preliminary Phase I findings across plaque psoriasis, atopic dermatitis and skin aging. It then moved into actinic keratosis, a precancerous skin condition associated with cumulative damage and aging.
The latest preliminary result is easy to understand: Rubedo reported a 46% reduction in actinic-keratosis lesions after four weeks of RLS-1496 treatment, with minimal irritation. The registered Phase I/II study is small, with around 24 participants, so the percentage is an early efficacy read rather than a definitive treatment effect.
Dermatology gives Rubedo a smart shortcut. Researchers can see lesions directly, biopsy the tissue, compare treated and untreated areas and get answers in weeks rather than waiting years for cardiovascular events or cognitive decline. Topical dosing also limits systemic exposure.
A successful actinic-keratosis drug would validate Rubedo's approach to senescent cells much sooner than a broad healthspan trial ever could. Whether that mechanism can later work systemically throughout an aging human body remains an open question.
If you want more recent data on this point, please see our latest longevity market report.
Is Life Biosciences already testing real human rejuvenation?
Life Biosciences is now running arguably the clearest human test of cellular rejuvenation in the longevity industry, but ER-100 has only reached Phase I, so commercialization remains a long way off.
ER-100 uses AAV2 gene delivery to express OCT4, SOX2 and KLF4 in retinal ganglion cells. Those three transcription factors are part of the Yamanaka-factor family used to reset cellular identity and epigenetic state. Life Biosciences is attempting controlled partial reprogramming rather than taking cells all the way back to pluripotency.
The FDA cleared the first-in-human study earlier this year, and Life Biosciences dosed its first participant in June. The trial includes people with open-angle glaucoma and non-arteritic anterior ischemic optic neuropathy. Safety and tolerability come first, while visual-function measures should provide an early look at whether rejuvenating older retinal cells has a useful clinical effect.
Partial epigenetic reprogramming spent years living mainly in cell cultures and animal experiments. It is now being administered to people.
The next hurdles are substantial: safe dosing, tight control of reprogramming, durability and eventually a clinically meaningful visual benefit in larger trials.
This chart, featured in our longevity market deck, illustrates yearly funding for longevity startups
What about Retro, NewLimit and Altos Labs — aren’t they the biggest rejuvenation bets?
Retro Biosciences is already in Phase I and therefore deserves more clinical credit than it used to, while NewLimit is preparing for human trials and Altos Labs remains much harder to rank as a near-term commercial drug company.
Retro is the biggest mover in this group. Its RTR242 small molecule, designed to boost autophagy and being developed around Alzheimer's disease, has reached first-in-human dosing. Retro says it went from selecting the indication to dosing its first human in about 15 months and now has additional clinical milestones planned across its pipeline.
That makes Retro more advanced than its old reputation as a giant long-term moonshot suggests. The company still has several much more radical programs behind RTR242, including iPSC-derived cell therapies, tissue reprogramming, AI-designed proteins and chemical rejuvenation. Those remain earlier.
NewLimit is moving quickly too, but its first reprogramming medicine is still preclinical. After raising $435 million in a new funding round, the company said it intends to take its first aging-reprogramming therapy into human trials next year. Its initial programs target old liver cells, vascular cells and immune cells.
Altos Labs remains the strange giant of the group. It launched with roughly $3 billion and has recruited extraordinary scientific talent around cellular rejuvenation, but it still does not publicly show the sort of clinical-stage lead drug that would put it near Insilico, BioAge or even Life Biosciences on our commercial ranking.
The comparison exposes how misleading funding can be in longevity. A multibillion-dollar research organization can be commercially behind a much smaller biotech that has already put a defined molecule into patients.
| Company | Clinical position now | Commercial interpretation |
|---|---|---|
| Retro Biosciences | RTR242 in Phase I | Real clinical contender, still early |
| Life Biosciences | ER-100 in Phase I | First human epigenetic-restoration program |
| NewLimit | First human trial planned for next year | Promising but still preclinical |
| Altos Labs | No comparable public late-stage program | Huge scientific bet, weak near-term ranking |
Is Longeveron closer to a longevity drug than people realize?
Longeveron deserves to rank higher than most longevity lists suggest because laromestrocel has already produced randomized Phase II evidence in aging-related frailty and the company's Alzheimer's program has a Phase III design aligned with the FDA.
Laromestrocel is an allogeneic mesenchymal stem-cell therapy being tested across several diseases. The program most directly tied to longevity is aging-related frailty, a syndrome of declining physical reserve for which there is currently no FDA-approved drug.
Results from Longeveron's Phase IIb frailty trial were published in Cell Stem Cell this year. The study found improvements in physical performance after nine months compared with placebo, including evidence around six-minute walking ability. Longeveron was subsequently selected as a finalist in the XPRIZE Healthspan competition partly on the strength of those clinical results.
The Alzheimer's program has also moved beyond a vague pipeline slide. Longeveron reported Phase IIa data and later presented analyses suggesting reduced neuroinflammation in gray and white matter. More importantly for our commercial ranking, the company says it has received RMAT designation from the FDA and aligned with the agency on the design of a Phase III Alzheimer's study.
Longeveron still sits behind Insilico because the Alzheimer's Phase III trial has not produced pivotal data, while rentosertib is already in late-stage testing. Cell therapy is also harder and more expensive to manufacture and distribute than an oral pill.
There is another wrinkle. Laromestrocel's most advanced near-term regulatory opportunity is hypoplastic left heart syndrome, a severe congenital heart condition in children. That could potentially bring the company closer to becoming commercial, but an approval there would obviously tell us very little about whether it has created a longevity medicine.
If you want more recent data on this point, please see our latest longevity market report.
This chart, featured in our longevity market deck, compares the main business model options for longevity clinics
Did Unity Biotechnology already lose the race to commercialize a senolytic drug?
Unity Biotechnology has effectively dropped out of the active longevity-drug race after UBX1325 missed its main Phase IIb statistical target and the company ceased clinical development.
Unity used to be the obvious company to watch. It was one of the best-funded pioneers of senolytics, drugs intended to eliminate harmful senescent cells. UBX1325 targeted BCL-xL and entered mid-stage trials for diabetic macular edema.
The earlier evidence looked good enough to keep the story alive for years. In the BEHOLD Phase II study, Unity reported a 6.2-letter mean improvement in visual acuity at 48 weeks after a single dose, while more than half of treated patients avoided additional anti-VEGF injections during the period.
The larger ASPIRE Phase IIb study produced a messier answer. UBX1325 generated visual-acuity improvements and later showed non-inferiority to aflibercept at individual time points, but it missed the prespecified primary analysis based on the average of weeks 20 and 24.
That miss became decisive financially. Unity's board approved a plan to close the study, cut its workforce and evaluate asset sales, licensing, a merger or dissolution. SEC documents say the company ceased all clinical development. Nasdaq later told Unity that it appeared to no longer have an operating business, and the company subsequently terminated its SEC registration.
Unity is useful to keep in the article because it shows how deceptive a simple pipeline ranking can be. UBX1325 technically progressed farther than several drugs we rank above it today. A Phase IIb asset with no active development organization, however, is much farther from pharmacies than an actively funded Phase II program.
Could Loyal beat every human longevity startup to an actual longevity drug?
Yes — if we include animals, Loyal is currently the company most likely to sell a drug explicitly designed to extend healthy lifespan before any human longevity startup can make the same claim.
LOY-002 is a once-daily pill for dogs aged ten or older and weighing at least 14 pounds. Loyal says the drug is intended to improve metabolic health and insulin sensitivity, preserve quality of life and extend lifespan.
Its regulatory position is unusually advanced. Loyal now lists two of the three major technical sections required for FDA expanded conditional approval as accepted: reasonable expectation of effectiveness and target-animal safety. Chemistry, manufacturing and controls remain in progress.
That's much more important than another encouraging dog study. Under the FDA's conditional-approval system for animal drugs, a company can legally market a medicine after establishing safety, proper manufacturing and a “reasonable expectation of effectiveness,” while continuing to collect the evidence required for full approval.
Dogs also make the experiment unusually useful. They share human homes, naturally develop cancer, metabolic disease, cognitive decline and other age-related conditions, yet their lives are short enough for lifespan trials to finish in a realistic period.
The FDA's Center for Veterinary Medicine operates under a different regulatory system, so success in dogs would not establish that the same intervention works in people. But Loyal could still create the first commercial prescription drug whose explicit purpose includes extending healthy lifespan.
This chart, featured in our longevity market deck, illustrates how revenue is distributed across customer segments in the longevity market
Which longevity startups are actually closest to a real commercial drug?
Insilico Medicine is currently the clear leader for a human drug, Loyal leads the literal lifespan-extension race in dogs, and a second group led by BioAge, Longeveron and Cambrian sits meaningfully behind Insilico but well ahead of the industry's preclinical moonshots.
Rentosertib gives Insilico the simplest case. It has completed Phase II, produced peer-reviewed human efficacy data and entered a 320-person Phase III study. None of the other major human longevity companies we reviewed has an active lead asset that far through development.
BioAge comes next among the most recognizably geroscience-driven small-molecule companies. BGE-102 has powerful early NLRP3 pharmacology and is now in Phase II, although it still needs to move from biomarker suppression toward clinically meaningful disease outcomes.
Longeveron deserves roughly the same tier for a different reason. Laromestrocel already has randomized Phase IIb data in aging-related frailty, while its Alzheimer's program has FDA RMAT designation and an agreed Phase III design. The product's cell-therapy format makes the commercial path harder than an oral drug, but the human evidence is more mature than many people realize.
Cambrian's ATX-304 follows closely. Its metabolic Phase I data justify the Phase II program, yet we still need to see a real treatment effect on obesity or cardiometabolic disease.
Rubedo is earlier but unusually interesting because RLS-1496 directly attacks pathological senescent cells and has already produced a preliminary lesion-reduction result in humans. A small topical study cannot settle the senolytic question, but Rubedo has moved beyond mouse data.
Life Biosciences and Retro Biosciences now form another important group. Both have entered Phase I, which is a major change from the days when ambitious rejuvenation companies existed almost entirely in preclinical research. Life Biosciences is attempting controlled epigenetic restoration in the eye. Retro has put its autophagy drug RTR242 into humans and has much more radical rejuvenation technologies behind it.
NewLimit could join that clinical group next if its planned first human reprogramming trial starts on schedule. Altos Labs remains scientifically formidable but still does not belong near the top of a commercial-readiness ranking based on publicly visible clinical assets.
Unity has fallen out of the active race. Its history remains relevant because UBX1325 reached Phase IIb before a missed primary endpoint and financial pressure led the company to stop clinical development entirely.
Then there is Loyal. LOY-002 has already cleared two of three major technical requirements on its route toward FDA conditional approval. If the manufacturing section clears too, the first drug commercially sold with an explicit healthy-lifespan objective could arrive for dogs while every human longevity company is still running trials.
The answer is therefore much clearer than it was a few years ago. Insilico has the only obvious late-stage lead in humans. BioAge, Longeveron and Cambrian form the most credible chasing group. Rubedo, Life Biosciences and Retro are testing more directly aging-oriented ideas but remain earlier.
Nobody has yet shown in a large controlled human trial that one medicine broadly slows aging across the body, and nobody can prescribe a human drug for that purpose today.
Insilico is closest to completing the first commercial step. The broader anti-aging claim remains wide open.
If you want more recent data on this point, please see our latest longevity market report.
OUR METHODOLOGY
We treated “closest to a real commercial drug” as a composite question rather than simply ranking longevity companies by trial phase, funding or scientific ambition. For each company, we focused on its most commercially advanced relevant program and compared clinical maturity, strength of human evidence, regulatory progress, development momentum, practical path to market and connection to aging biology.
We gave the most weight to active human development. Larger randomized studies counted more than small exploratory trials, pivotal programs counted more than plans to start trials, regulatory actions counted more than projected timelines, and clinical outcomes counted more than mechanistic biomarkers alone.
Trial phase therefore influenced the ranking without determining it mechanically. Unity Biotechnology is the clearest example: UBX1325 once reached Phase IIb, but the company ceased clinical development, so that historical milestone no longer makes Unity commercially closer than companies with earlier but actively funded programs.
We also separated scientific directness from commercial proximity. A program based on partial epigenetic reprogramming or cellular rejuvenation may target aging more directly than rentosertib, while still sitting years behind it commercially. Conversely, a disease-specific medicine can rank first if it came out of aging biology and is much closer to regulatory approval.
Human medicines were compared primarily with other human medicines. Loyal was treated separately because LOY-002 is explicitly intended to extend healthy lifespan but follows the FDA Center for Veterinary Medicine's conditional-approval pathway, which has a different regulatory standard from human drug approval.
For Insilico Medicine, the main evidence included the Nature Medicine Phase IIa rentosertib study, Insilico's Phase III initiation announcement, and the Nature Biotechnology proteomic aging-clock analysis. We treated the aging-clock result as exploratory evidence rather than proof of slowed human aging.
For BioAge, we used the company's BGE-102 Phase I results, its QUELL-CV Phase II update, and the corresponding ClinicalTrials.gov record. For Cambrian, we used its clinical pipeline together with the American Diabetes Association report on ATX-304's Phase Ib study.
For the more directly aging-oriented programs, key sources included the registered RLS-1496 study and Rubedo's clinical updates, Life Biosciences' ER-100 first-patient announcement and ClinicalTrials.gov record, Retro Biosciences' pipeline and 2026 clinical update, NewLimit's $435 million financing and development update, and Altos Labs' description of its cellular-rejuvenation science.
For Longeveron, we relied most heavily on the Cell Stem Cell randomized Phase IIb frailty study and the company's Alzheimer's clinical and regulatory update. Unity's position was based on its corporate filing documenting the cessation of clinical development.
For Loyal, we used its disclosures on the FDA's acceptance of the reasonable-expectation-of-effectiveness section and target-animal-safety section, together with FDA guidance on what expanded conditional approval permits. Across the article, we prioritized peer-reviewed studies, ClinicalTrials.gov records, FDA material, regulatory filings and direct company disclosures that added specific, checkable information.
This chart, featured in our longevity market deck, shows how longevity plan technology has evolved over time
Related blog posts
